Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

NCT04001634 · clinicaltrials.gov ↗
COMPLETED
Status
285
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Fudan University